Blood disorders can be caused by inherited genetic mutations, environmental insults, drugs or nutritional deficiencies. Common hematological disorders include hemophilia (impaired clotting ability), clotting disorders (predisposition to form blood clots), blood cancers (i.e., liquid tumors) such as leukemias, lymphomas, and myelomas, anemia, and thrombocytopenia. Related drugs could be applied for the indications above.
This report contains market size and forecasts of Hematology Indications Related Drugs in global, including the following market information:
Global Hematology Indications Related Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Hematology Indications Related Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Hematology Indications Related Drugs companies in 2021 (%)
The global Hematology Indications Related Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cyclooxygenase Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hematology Indications Related Drugs include Gilead, Bayer, Owkin, Amgen, Alexion Pharmaceuticals, AllCells, LLC, Kiadis Pharma, Bicycle Therapeutics and Rennova Health, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hematology Indications Related Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematology Indications Related Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Hematology Indications Related Drugs Market Segment Percentages, by Type, 2021 (%)
Cyclooxygenase Inhibitors
Antiplatelet Agents
Thrombin Inhibitors
Demethylating Agents
Global Hematology Indications Related Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Hematology Indications Related Drugs Market Segment Percentages, by Application, 2021 (%)
Relieve Hematological Complications
Diease Thearpy
Global Hematology Indications Related Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Hematology Indications Related Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematology Indications Related Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Hematology Indications Related Drugs revenues share in global market, 2021 (%)
Key companies Hematology Indications Related Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Hematology Indications Related Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead
Bayer
Owkin
Amgen
Alexion Pharmaceuticals
AllCells, LLC
Kiadis Pharma
Bicycle Therapeutics
Rennova Health
Sierra Oncology
Spectrum Pharmaceuticals, Inc.
Astex Therapeutics
Nucentra
Novo A/S